TAO Synergies Inc.: Form 10-Q for the period ended Sep 30, 2023
Filed with the SEC on Nov 14, 2023 and accepted by EDGAR at Nov 14, 2023, 17:00 ET.
Management's discussion and analysis
As filed, 36,205 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes appearing elsewhere in this report. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section titled “Risk Factors” included elsewhere in this report and our annual report on Form 10-K for the year ended December 31, 2022.
The following discussion highlights our results of operations and the principal factors that have affected our financial condition as well as our liquidity and capital resources for the periods described, and provides information that management believes is relevant for an assessment and understanding of the statements of financial condition and results of operations presented herein. The following discussion and analysis are based on the unaudited financial statements contained in this report, which we have prepared in accordance with United States generally accepted accounting principles. You should read the discussion and analysis together with such financial statements and the related notes thereto.
Basis of Presentation
The unaudited financial statements for the nine months ended September 30, 2023 and 2022 include a summary of our significant accounting policies and should be read in conjunction with the discussion below and our financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations for such periods have been included in the financial statements. All such adjustments are of a normal recurring nature.
Overview
We are a biopharmaceutical company with product candidates in pre-clinical and clinical development. We began operations in October 2012. We are principally focused on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease, which is in the clinical testing stage. We are also evaluating Bryostatin-1 for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.
Neurotrope, our predecessor company, had been a party to a technology license and services agreement with the original Blanchette Rockefeller Neurosciences Institute (which has been known as Cognitive Research Enterprises, Inc. since October 2016), and its affiliate NRV II, LLC, which we collectively refer to herein as “CRE,” pursuant to which we now have an exclusive non-transferable license to certain patents and technologies required to develop our proposed products. We were formed for the primary purpose of commercializing the technologies initially developed by BRNI for therapeutic applications for AD or other cognitive dysfunctions. These technologies have been under development by BRNI since 1999 and, until March 2013, had been financed through funding from a variety of non-investor sources (which include not-for-profit foundations, the NIH, which is part of the U.S. Department of Health and Human Services, and individual philanthropists). From March 2013 forward, development of the licensed technology has been funded principally through us in collaboration with CRE.
November 2022 Private Placement
On November 17, 2022, we entered into the November Purchase Agreement with the November Investors, pursuant to which we agreed to sell to the November Investors (i) an aggregate of 15,000 shares of Series B Preferred Stock and (ii) November Warrants to acquire up to an aggregate of 1,935,485 shares of Common Stock. We received total gross proceeds of approximately $15 million from the November Private Placement.
The terms of the Series B Preferred Stock are as set forth in the Certificate of Designations. The Series B Preferred Stock will be convertible into Series B Preferred Shares at the election of the holder at any time at the Conversion Price. The Conversion Price is subject to customary adjustments for stock dividends, stock splits, reclassifications and the like, and subject to price-based adjustment in the event of any issuances of Common Stock, or securities convertible, exercisable or exchangeable for Common Stock, at a price below the then-applicable Conversion Price (subject to certain exceptions). We will be required to redeem the Series B Preferred Stock in 15 equal monthly installments, commencing on June 1, 2023. The amortization payments due upon such redemption are payable, at our election, in cash, or subject to certain limitations, in shares of Common Stock valued at the lower of (i) the Conversion Price then in effect and (ii) the greater of (A) a 15% discount to the average of the three lowest closing prices of the Common Stock during the thirty trading day period immediately prior to the date the amortization payment is due or (B) the lower of $1.25 and $0.172, which is equal to 20% of the Minimum Price (as defined in Rule 5635 of the Rule of the Nasdaq Stock Market) on April 14, 2023, the date of receipt of Nasdaq Stockholder Approval (as defined below); provided that if the amount set forth in clause B is the lowest effective price, we will be required to pay the amortization payment in cash. We may require holders to convert their Series B Preferred Stock into Series B Preferred Shares if the closing price of the Common Stock exceeds $11.625 per share for 20 consecutive trading days and the daily trading volume of the Common Stock exceeds 100,000 shares per day during the same period and certain equity conditions described in the Certificate of Designations are satisfied.
The holders of the Series B Preferred Stock are entitled to dividends of 7% per annum, compounded monthly, which are payable in cash or shares of Common Stock at our option, in accordance with the terms of the Certificate of Designations. Upon the occurrence and during the continuance of a Triggering Event (as defined in the Certificate of Designations), the Series B Preferred Stock will accrue dividends at the rate of 15% per annum. The holders of Series B Preferred Stock have no voting rights on account of the Series B Preferred Stock, other than with respect to certain matters affecting the rights of the Series B Preferred Stock.
Notwithstanding the foregoing, our ability to settle conversions and make amortization payments using shares of Common Stock is subject to certain limitations set forth in the Certificate of Designations, including a limit on the number of shares that may be issued until the time, if any, that our stockholders have approved the issuance of more than 19.9% of our outstanding shares of Common Stock in accordance with Nasdaq listing standards (the “Nasdaq Stockholder Approval”). We agreed to seek stockholder approval of these matters at a meeting to be held no later than June 1, 2023, and such approval was obtained at the Company’s special meeting of stockholders held on April 14, 2023. Further, the Certificate of Designations contains a certain beneficial ownership limitation after giving effect to the issuance of shares of Common Stock issuable upon conversion of, or as part of any amortization payment under, the Certificate of Designations or November Warrants.
The Certificate of Designations includes certain Triggering Events (as defined in the Certificate of Designations), including, among other things, the failure to file and maintain an effective registration statement covering the sale of the holder’s securities registrable pursuant to the November Registration Rights Agreement (defined below) and our failure to pay any amounts due to the holders of the Series B Preferred Stock when due. In connection with a Triggering Event, each holder of Series B Preferred Stock will be able to require us to redeem in cash any or all of the holder’s Series B Preferred Stock at a premium set forth in the Certificate of Designations.
We are subject to certain affirmative and negative covenants regarding the incurrence of indebtedness, acquisition and investment transactions, the existence of liens, the repayment of indebtedness, the payment of cash in respect of dividends (other than dividends pursuant to the Certificate of Designations), distributions or redemptions, and the transfer of assets, among other matters.
The November Warrants are exercisable for Warrant Shares immediately at an exercise price of $7.75 per share (the “Exercise Price”) and expire five years from the date of issuance. The Exercise Price is subject to customary adjustments for stock dividends, stock splits, reclassifications and the like, and subject to price-based adjustment, on a “full ratchet” basis, in the event of any issuances of Common Stock, or securities convertible, exercisable or exchangeable for Common Stock, at a price below the then-applicable Exercise Price (subject to certain exceptions).
In connection with the November Purchase Agreement, we and the November Investors entered into a Registration Rights Agreement (the “November Registration Rights Agreement”) on November 17, 2022. Under the terms of the November Registration Rights Agreement, we agreed to register 200% of the Series B Preferred Shares, the Warrant Shares and the shares of Common stock issuable as amortization payments as well as any shares of Common stock paid as dividends. We filed a registration statement for the resale of such securities on December 16, 2022. We also agreed to other customary obligations regarding registration, including indemnification and maintenance of the effectiveness of the registration statement.
In connection with the November Private Placement, pursuant to an Engagement Letter, between the Company and Katalyst Securities LLC (the “November Placement Agent”), we paid the November Placement Agent (i) a cash fee equal to 7% of the gross proceeds from any sale of securities in the November Private Placement and (ii) warrants to purchase shares of Common Stock equal to 3% of the number of shares of Common Stock that the Series B Preferred Shares are initially convertible into, with an exercise price of $7.75 per share and a five-year term.
During the three months ended September 30, 2023, we redeemed $3,000,000 of the Series B Preferred Stock and $192,500 of accrued dividends by issuing 8,086,785 shares of our Common Stock through installment conversions and proportionately relieved $2,455,656 of discount related to the redeemed Series B Preferred Stock. During the three months ended September 30, 2023, we recognized a deemed dividend of $932,128 related to true-up conversion shares in excess of the pre-amortization installment amounts and issued 2,047,526 shares of our Common Stock in satisfaction of the deemed dividend.
During the nine months ended September 30, 2023, we redeemed $6,000,000 of the Series B Preferred Stock and $882,149 of accrued dividends through a combination of cash and by issuing 8,086,785 shares of our Common Stock through installment conversions and proportionately relieved $4,911,312 of discount related to the redeemed Series B Preferred Stock. During the nine months ended September 30, 2023, we recognized a deemed dividend of $1,010,274 related to cash premiums and true-up conversion shares in excess of the pre-amortization installment amounts and issued 2,047,526 shares of our Common Stock in satisfaction of the deemed dividend.
As of September 30, 2023, we have accrued a liability for installment payments owed to investors in either cash or shares of $1,527,001.
Results of Most Recent Extended Confirmatory Phase 2 Clinical Trial
On July 23, 2020, we entered into the 2020 Services Agreement with WCT. The 2020 Services Agreement relates to services for our Phase 2 clinical study assessing the safety, tolerability and long-term efficacy of Bryostatin-1 in the treatment of moderately severe AD subjects not receiving memantine treatment. On January 22, 2022, the Company executed a change order with WCT to accelerate trial subject recruitment totaling approximately $1.4 million. The updated total estimated budget for the services, including pass-through costs, is approximately $11.0 million. As previously disclosed, on January 22, 2020, we were granted a $2.7 million award from the NIH, which award is being used to support the 2020 Study, resulting in a current estimated net budgeted cost of the 2020 Study to us of $8.3 million. Of the $2.7 million grant, virtually all has been received as of February 22, 2022.
As of September 30, 2023, we incurred cumulative expenses of approximately $10.6 million associated with services provided by WCT and certain pass-through expenses incurred by WCT, which was offset by NIH reimbursements recognized of $2.7 million and, for the three and nine months ended September 30, 2023, we incurred expenses of approximately $145,000 and $0.5 million associated with services provided by WCT and certain pass-through expenses incurred by WCT.
On December 16, 2022, we issued a press release announcing that an extended confirmatory Phase 2 study of Bryostatin-1 in moderate to severe AD (Study #204) did not achieve statistical significance on the primary endpoint, which was change from baseline to Week 13 in the SIB total score assessment obtained after completion of the second seven-dose course of treatment (week 28 of trial). On March 7, 2023, we announced results of our analysis of secondary endpoints and post hoc analysis from our Phase 2 study of Bryostatin-1. In the secondary endpoint analysis, changes from baseline at Weeks 9, 20, 24, 30, and 42 in the SIB (Severe Impairment Battery) total score were not statistically significant in the total patient population, and no pre-specified secondary endpoints were met with statistical significance in the low-to-moderately severe AD patient stratum. However, nearly all pre-specified secondary endpoints in the most advanced and severe AD (MMSE: 10-14) patient population, with baseline MMSE-2 (Mini-Mental State Examination, 2nd Edition) scores of 10-14, were achieved with statistical significance (p = <0.05, 2-tailed). Data also showed statistical significance in exploratory secondary endpoints for the MMSE-2 10-14 stratum, and post hoc analysis was positive.
Open Label Dose Ranging Clinical Trial
On May 12, 2022, the Company entered into a services agreement with WCT (the “2022 Services Agreement”). The 2022 Services Agreement relates to services for a Phase 2 “open label,” dose ranging study, clinical trial assessing the safety, tolerability and efficacy of Bryostatin-1 administered via infusion in the treatment of moderately severe to severe AD subjects not receiving memantine treatment (the “2022 Study”).
Pursuant to the terms of the 2022 Services Agreement, WCT provided services to enroll approximately 12 2022 Study subjects. The first 2022 Study site was initiated during the third quarter of 2022. The total estimated budget for the services, including pass-through costs, is currently approximately $1.5 million. Either party may terminate the 2022 Services Agreement without cause upon 90 days prior written notice. Furthermore, in the event of a material breach by the other party, which breach is not cured by the breaching party, the other party may terminate the agreement upon 30 days’ prior written notice. The Company terminated the 2022 Services Agreement in December 2022.
The Company incurred approximately $1.5 million of cumulative expenses associated with the current 2022 Study as of September 30, 2023. Of the total $1.4 million incurred for the trial as of September 30, 2023, approximately $14,000 and $171,000 is reflected in the statement of operations for the three and nine months ended September 30, 2023, respectively, and $0 for the comparable 2022 periods. As of September 30, 2023, $0 of WCT 2022 Study prepayments is included as a prepaid expense and other current assets in the Company’s balance sheet. In addition, approximately $26,000 is included in accounts payable and accrued expenses as of September 30, 2023.
Other Development Projects
To the extent resources permit, we may pursue development of selected technology platforms with indications related to the treatment of various disorders, including neurodegenerative disorders such as AD, based on our currently licensed technology and/or technologies available from third party licensors or collaborators.
Nemours Agreement
On September 5, 2018, we announced a collaboration with Nemours, a premier U.S. children’s hospital, to initiate a clinical trial in children with Fragile X. In addition to the primary objective of safety and tolerability, measurements will be made of working memory, language and other functional aspects such as anxiety, repetitive behavior, executive functioning, and social behavior. On August 5, 2021, the Company announced its memorandum of understanding with Nemours A.I. DuPont Hospital (“Nemours”) to initiate a clinical trial using Bryostatin-1, under Orphan Drug Status, to treat Fragile X. We intend to provide the Bryostatin-1 drug product candidate and obtain the IND and Nemours intends to provide the clinical site and attendant support for the trial. We and Nemours, jointly, will develop the trial protocol. We currently estimate our total trial and IND cost to be approximately $2 million. As of September 30, 2023, we have incurred cumulative expenses associated with this agreement of approximately $100,000.
We have filed for an IND with the FDA. The FDA has placed the development of the IND on clinical hold pending completion of further analytics relating to drug pharmacokinetics and pharmacodynamics. We are currently evaluating its plans to advance Fragile X development.
Cleveland Clinic
On February 23, 2022, we announced our collaboration with the Cleveland Clinic to pursue possible treatments for Multiple Sclerosis, and on July 19, 2023, we announced that we had entered into an agreement with Cleveland Clinic to conduct a Phase 1 trial of Bryostatin-1 in MS. Cleveland Clinic will manage the clinical trial’s implementation, including an IND submission to the FDA and patient enrollment. The total estimated costs associated with this collaboration are approximately $2.0 million. As of September 30, 2023, the Company has paid the Cleveland Clinic approximately $375,000.
Results of Operations
Comparison of the nine months ended September 30, 2023 and 2022
The following table summarizes our results of operations for the nine months ended September 30, 2023 and 2022:
| Operating Expenses: | | Nine Months ended September 30, 2023 | | 2022 | | Dollar Change | | % Change |
|---|---|---|---|---|---|---|---|---|
| Research and development expenses | | $1,397,031 | | $4,911,869 | | $(3,514,838) | | (71.6)% |
| General and administrative expenses | | $4,784,415 | | $5,334,260 | | $(549,845) | | (10.3)% |
| Other income (loss), net | | $1,138,911 | | $189,827 | | $949,084 | | 500.0% |
| Net loss | | $5,042,535 | | $10,056,302 | | $(5,013,767) | | (49.9)% |
Operating Expenses
Overview
Total operating expenses for the nine months ended September 30, 2023 were $6,181,446 as compared to $10,246,129 for the nine months ended September 30, 2022, a decrease of approximately 39.7%. The decrease in total operating expenses is due to the decrease in research and development activities and general and administrative expenses.
Research and Development Expenses
For the nine months ended September 30, 2023, we incurred $1,397,031 in research and development expenses as compared to $4,911,869 for the nine months ended September 30, 2022, a decrease of approximately 71.6%. These expenses were incurred primarily pursuant to developing the potential AD therapeutic product, specifically expenses relating to our ongoing Phase 2 clinical trial for AD. Of these expenses, for the nine months ended September 30, 2023, $938,003 was incurred principally relating to our current confirmatory clinical trial and our Phase 2 dose ranging study and related storage of drug product, $252,752 for clinical consulting services, $15,288 of amortization of prepaid licensing fees relating to the Stanford License Agreement and Mount Sinai Agreement, $41,399 for development of alternative drug supply with Stanford University and $149,589 of non-cash stock options compensation expense; comparatively, for the nine months ended September 30, 2022, $4,230,427 was incurred principally relating to our confirmatory clinical trial and related storage of drug product, $237,908 for clinical consulting services, $22,439 of amortization of prepaid licensing fees relating to the Stanford License Agreement and Mount Sinai Agreement, $41,562 for development of alternative drug supply with Stanford University and $379,533 of non-cash stock options compensation expense.
Our research and development expenses are leveling off as our current Phase 2 clinical trial for AD was materially concluded by the end of 2022 and our Phase 2 dose ranging study was discontinued. Other development expenses might increase, as our resources permit, in order to advance our potential products. We are continuing to determine how to proceed with respect to our other current development programs for Bryostatin-1.
General and Administrative Expenses
We incurred $4,784,415 and $5,334,260 of general and administrative expenses for the nine months ended September 30, 2023 and 2022, respectively, a decrease of approximately 10.3%. During the nine months ended September 30, 2023, $948,689 was incurred primarily for wages, bonuses, vacation pay, severance, taxes and insurance, versus $905,385 for the nine months ended September 30, 2022; $673,882 was incurred for legal expenses versus $310,053 for the 2022 comparable period. The increase in legal fees for 2023 is based upon the increased fees for special stockholder vote requirements and for regulatory compliance; $720,159 was incurred for outside operations consulting services during the nine months ended September 30, 2023, versus $792,954 for the comparable period in 2022; $122,196 was incurred for travel expenses during the nine months ended September 30, 2023, versus $62,908 for the comparable period in 2022 as post-COVID travel has increased; $303,271 was incurred for investor relations services during the nine months ended September 30, 2023, versus $495,831 for the comparable period in 2022, with the decrease for the current period based upon engaging additional consultants to assist with Company communications during the prior period; $245,021 was incurred for professional fees associated with auditing, financial, accounting and tax advisory services during the nine months ended September 30, 2023, versus $143,569 for the comparable period in 2022. The increase for the current period is primary attributable to additional audit work for the November Private Placement and auditor change; $577,950 was incurred for insurance during the nine months ended September 30, 2023, versus $547,898 for the comparable period in 2022; $348,575 was incurred for utilities, supplies, license fees, filing costs, rent, advertising and other during the nine months ended September 30, 2023, versus $216,200 for the comparable period in 2022, with the increase for 2023 primarily attributable to recognizing Delaware franchise tax quarterly; and $844,672 was recorded as non-cash stock options compensation expense during the nine months ended September 30, 2023, versus $1,859,462 for the comparable period in 2022.
Other Income / Expense
We recognized total other income of $1,138,911 for the nine months ended September 30, 2023 as compared to total other income of $189,827 for the nine months ended September 30, 2022, which consisted, for 2023, of interest income on funds deposited in interest bearing money market accounts and changes in fair value of warrant liability and derivative liability versus interest income only for 2022. The increase in interest income of $1,183,684 is primarily attributable to the increase in money market interest income rates and increase in cash balances. The total increase is primarily attributable to the increase in interest income and decrease in fair value of warrant liability of $1,055,000 partially offset by and the increase in fair value of derivative liability of $1,289,600.
Net loss
We incurred losses of $5,042,535 and $10,056,302 for the nine months ended September 30, 2023 and 2022, respectively. The decreased loss was primarily attributable to the decrease in net research and development expenses associated with our current Phase 2 confirmatory clinical trial and general and administrative expenses partially offset by an increase in other income.
Comparison of the three months ended September 30, 2023 and 2022
The following table summarizes our results of operations for the three months ended September 30, 2023 and 2022:
| Operating Expenses: | | Three Months ended September 30, 2023 | | 2022 | | Dollar Change | % Change |
|---|---|---|---|---|---|---|---|
| Research and development expenses | | $212,103 | | $1,484,694 | | $(1,272,591) | (85.7)% |
| General and administrative expenses | | $1,217,689 | | $1,682,512 | | $(464,823) | (27.6)% |
| Other income (loss), net | | $2,192,995 | | $140,730 | | $2,052,265 | 1,458.3% |
| Net loss (income) | | $(763,203) | | $3,026,476 | | $3,789,679 | (125.2)% |
Operating Expenses
Overview
Total operating expenses for the three months ended September 30, 2023 were $1,429,792 as compared to $3,167,206 for the three months ended September 30, 2022, a decrease of approximately 54.9%. The decrease in total operating expenses is due to the decrease in research and development activities and general and administrative expenses.
Research and Development Expenses
For the three months ended September 30, 2023, we incurred $212,103 in research and development expenses as compared to $1,484,694 for the three months ended September 30, 2022, a decrease of approximately 85.7%. These expenses were incurred primarily in connection with developing the potential AD therapeutic product, specifically expenses relating to our ongoing Phase 2 clinical trial for AD. Of these expenses, for the three months ended September 30, 2023, $95,248 was incurred principally relating to our current confirmatory clinical trial and our Phase 2 dose ranging study and related storage of drug product, $96,883 for clinical consulting services, $5,041 of amortization of prepaid licensing fees relating to the Stanford License Agreement and Mount Sinai Agreement, 14,931 for development of alternative drug supply with Stanford University and $0 of non-cash stock options compensation expense; comparatively, for the three months ended September 30, 2022, $1,287,025 was incurred principally relating to our confirmatory clinical trial and related storage of drug product, $85,250 for clinical consulting services, $7,508 of amortization of prepaid licensing fees relating to the Stanford License Agreement and Mount Sinai Agreement, $18,081 for development of alternative drug supply with Stanford University and $86,830 of non-cash stock options compensation expense.
Our research and development expenses have significantly decreased as our current Phase 2 clinical trial for AD was materially concluded by the end of 2022 and our Phase 2 dose ranging study was discontinued. Other development expenses might increase, as our resources permit, in order to advance our potential products. We are continuing to determine how to proceed with respect to our other current development programs for Bryostatin-1.
General and Administrative Expenses
We incurred $1,217,689 and $1,682,512 of general and administrative expenses for the three months ended September 30, 2023 and 2022, respectively, a decrease of approximately 27.6%. During the three months ended September 30, 2023, $300,598 was incurred primarily for wages, bonuses, vacation pay, severance, taxes and insurance, versus $303,879 for the three months ended September 30, 2022; $180,566 was incurred for legal expenses versus $103,033 for the 2022 comparable period. The increase in legal fees for 2023 is based upon the prior year’s increased fees for special stockholder vote requirements and for regulatory compliance; $247,344 was incurred for outside operations consulting services during the three months ended September 30, 2023, versus $203,500 for the comparable period in 2022; $48,148 was incurred for travel expenses during the three months ended September 30, 2023, versus $23,777 for the comparable period in 2022 as post-COVID travel has increased; $62,643 was incurred for investor relations services during the three months ended September 30, 2023, versus $362,262 for the comparable period in 2022; $59,812 was incurred for professional fees associated with auditing, financial, accounting and tax advisory services during the three months ended September 30, 2023, versus $33,844 for the comparable period in 2022. The increase for the current period is primary attributable to additional audit work for the November Private Placement and auditor change; $190,786 was incurred for insurance during the three months ended September 30, 2023, versus $182,354 for the comparable period in 2022; $112,728 was incurred for utilities, supplies, license fees, filing costs, rent, advertising and other during the three months ended September 30, 2023, versus $45,945 for the comparable period in 2022; and $15,064 was recorded as non-cash stock options compensation expense during the three months ended September 30, 2023, versus $423,917 for the comparable period in 2022.
Other Income / Expense
We recognized total other income of $2,192,995 for the three months ended September 30, 2023 as compared to a total other income of $140,730 for the three months ended September 30, 2022, which consisted, for 2023, of interest income on funds deposited in interest bearing money market accounts and changes in fair value of warrant liability and derivative liability versus interest income only for 2022. The increase in interest income of $409,265 is primarily attributable to the increase in money market interest income rates and increase in cash balances. The total increase is primarily attributable to the increase in interest income, the decrease in fair value of warrant liability of $674,000 and decrease in fair value of derivative liability of $969,000.
Net loss
We recognized income of $763,203 versus losses of $3,026,476 for the three months ended September 30, 2023 and 2022, respectively. The decreased loss was primarily attributable to the increase in other income and the decreases in net research and development expenses associated with our current Phase 2 confirmatory clinical trial and decrease in general and administrative expenses.
Financial Condition, Liquidity and Capital Resources
Cash and Working Capital
Since inception, we have incurred negative cash flows from operations. As of September 30, 2023, we had working capital of $30,522,980 as compared to working capital of $37,272,851 as of December 31, 2022. The $6,749,871 decrease in working capital was primarily attributable to approximately $6.3 million of operating expenses, preferred stock dividends of approximately $0.7 million and uses of cash of approximately $1.8 million partially offset by non-cash expenses of approximately $1.1 million and interest income of approximately $1.4 million.
We expect that our current cash and cash equivalents of approximately $29.5 million will be sufficient to support our projected operating requirements for at least the next 12 months from the date of this Quarterly Report on Form 10-Q, which would include the continuing development of Bryostatin-1, our novel drug candidate targeting the activation of PKCε, our initiation and possible development of a therapeutic for MS and other possible therapeutics.
We expect to require additional capital in order to initiate, pursue and complete all potential AD clinical trials and obtain regulatory approval of one or more therapeutic candidates. However, additional future funding may not be available to us on acceptable terms, or at all. If we are unable to access additional funds when needed, we may not be able to initiate, pursue and complete all planned clinical trials or continue the development of our product candidates or we could be required to delay, scale back or eliminate some or all of our development programs and operations. Any additional equity financing, if available, may not be available on favorable terms, would most likely be significantly dilutive to our current stockholders and debt financing, if available, and may involve restrictive covenants. If we are able to access funds through collaborative or licensing arrangements, we may be required to relinquish rights to some of our technologies or product candidates that we would otherwise seek to develop or commercialize on our own, on terms that are not favorable to us. Our ability to access capital when needed is not assured and, if not achieved on a timely basis, would likely materially harm our business and financial condition.
Sources and Uses of Liquidity
We expect to continue to incur expenses, resulting in losses and negative cash flows from operations, over at least the next several years as we continue to develop AD and other therapeutic products. We anticipate that this development may include clinical trials in addition to our current ongoing clinical trial and additional research and development expenditures.
| | | Nine Months Ended September 30, 2023 | | 2022 |
|---|---|---|---|---|
| Cash used in operating activities | | $4,107,209 | | $8,427,727 |
| Cash used in investing activities | | 2,707 | | 5,275 |
| Cash used in (provided by) financing activities | | 1,641,015 | | (553,150) |
Net Cash Used in Operating Activities
Cash used in operating activities was $4,107,209 for the nine months ended September 30, 2023, compared to $8,427,727 for the nine months ended September 30, 2022. The $4,320,518 decrease primarily resulted from the decrease in net loss of approximately $5.0 million, the increase in prepaid expenses of approximately $0.2 million, the increase in accounts payable and accrued expenses of approximately $0.4 million, and the changes in fair value of non-cash warrant and derivative liabilities totaling approximately $0.2 partially offset by an increase in non-cash stock-based compensation and consulting fees of approximately $1.5 million.
Net Cash Used in Investing Activities
Net cash used in investing activities was $2,707 for the nine months ended September 30, 2023 compared to $5,275 for the nine months ended September 30, 2022. The cash used in investing activities for the nine months ended September 30, 2023 was for capital expenditures.
Net Cash Used in / Provided by Financing Activities
Net cash used in financing activities was $1,641,015 for the nine months ended September 30, 2023 compared to cash provided by financing activities of $553,150 for the nine months ended September 30, 2022. The net cash used in financing activities for the 2023 period was for paying dividends and redeeming part of the investment made by investors in the November Private Placement. Funds provided by financing activities for the comparable 2022 period resulted from the exercise of investor warrants issued in 2021.
Controls and procedures
As filed, 3,397 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
An evaluation was performed under the supervision and with the participation of our Chief Executive Officer and our Chief Financial Officer, our principal executive officer and principal financial and accounting officer, respectively, of the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) or 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this report. Based on their evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures are not effective due to: inadequate segregation of duties consistent with control objectives in the areas over certain payroll and banking systems and user access controls; ineffective processes over period end financial disclosure and reporting including documentation of GAAP disclosure and reporting reviews supporting the financial reporting process and changes to chart of accounts; and ineffective information technology (IT) general computing controls including lack of risk and design assessments supporting IT security policies and procedures, user access, and IT controls within third party contracts. These weaknesses may affect management’s ability to determine if errors or inappropriate actions have taken place. Management is required to apply its judgment in evaluating the cost-benefit relationship of possible changes in our disclosure controls and procedures.
We previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, that our management, including our Chairman of the Board, principal executive officer and principal financial and accounting officer, assessed the effectiveness of our internal control over financial reporting based on the criteria for effective internal control over financial reporting established in the 2013 Internal Control— Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) and SEC guidance on conducting such assessments. Based on that evaluation, they concluded that, during the period covered by the Annual Report on Form 10-K for the fiscal year ended December 31, 2022, such internal controls and procedures were not effective to detect the inappropriate application of US generally accepted accounting principles.
Based on management’s review, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were ineffective as of September 30, 2023. Notwithstanding the material weaknesses described above, our management, including the Chief Executive Officer and Chief Financial Officer, has concluded that financial statements, and other financial information included in this Quarterly Report on Form 10-Q, fairly present in all material respects our financial condition, results of operations, and cash flows as of and for the periods presented in this Quarterly Report on Form 10-Q.
Changes in Internal Controls over Financial Reporting
There was no change in our internal controls over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q, which has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting.
PART II
OTHER INFORMATION
Risk factors
As filed, 463 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
You should carefully review and consider the information regarding certain factors that could materially affect our business, consolidated financial condition or results of operations set forth under Item 1A. Risk Factors in our 2022 Annual Report on Form 10-K. There have been no material changes from the risk factors disclosed in our 2022 Annual Report on Form 10-K. We may disclose changes to risk factors from time to time in our future filings with the SEC.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2023-07-01 to 2023-09-30 | $212.1k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2023-01-01 to 2023-09-30 | $1.4m | us-gaap:ResearchAndDevelopmentExpense |
| Net income | 3 months2023-07-01 to 2023-09-30 | $763.2k | us-gaap:NetIncomeLoss |
| Net income | 9 months2023-01-01 to 2023-09-30 | −$5.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-07-01 to 2023-09-30 | $0.03 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2023-01-01 to 2023-09-30 | $1.48 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-07-01 to 2023-09-30 | $0.03 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2023-01-01 to 2023-09-30 | $1.48 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-07-01 to 2023-09-30 | 10,702,900 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2023-01-01 to 2023-09-30 | 8,476,200 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2023-01-01 to 2023-09-30 | −$4.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2023-01-01 to 2023-09-30 | $2.7k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2023-09-30 | $31.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-09-30 | $32.3m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-09-30 | $32.4m | us-gaap:Assets |
| Current liabilities | At period end2023-09-30 | $1.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-09-30 | $3.9m | us-gaap:Liabilities |
| Shareholders' equity | At period end2023-09-30 | $26.7m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001410578-23-002492. Last ingested by Listed: Nov 2, 2026, 06:08 ET. Listed shows no prices and gives no investment advice.